Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

NCT04459065 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: IRDye800CW-nimotuzumab

Sponsor

University of Saskatchewan

Collaborators

[object Object]